Overview

To Assess the Bioavailability of TK-254RX in Comparison with Oral Flurbiprofen Tablets and the Adhesion of TK-254RX in Healthy Subjects

Status:
COMPLETED

Trial end date:
2025-02-24

Target enrollment:

Participant gender:

Summary

This study is a single-center, open-label, multiple-dose trial performed in a 2-period, 2- sequence-cross-over design in healthy volunteers. The primary purpose of this study is to assess non-superiority of the bioavailability of TK-254RX compared with that of a marketed oral flurbiprofen-containing tablet formulation in healthy volunteers in a 2-period, 2- sequence-cross-over design and evaluate adhesion of TK-254RX. Secondary purpose is to assess safety of TK-254RX and residual amount of the patch.

Phase:

PHASE1

Details

Lead Sponsor:

Teikoku Seiyaku Co., Ltd.

Collaborators:

HWI pharma services GmbH
SocraMetrics GmbH
SocraTec R&D GmbH

Treatments:

Flurbiprofen